Johnson & Johnson highlights gains for Tylenol

20 April 2017 - Deborah Wilkes

Archived

Johnson & Johnson reported a 2.4% increase in its US OTC sales during the first quarter of 2017, thanks to the "strength" of its Tylenol analgesics.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: